Swiss companies funneled $27 billion into the United States in just the first four months of 2026. The catalyst was a trade framework agreement announced on November 14, 2025, which slashed US tariffs on Swiss goods from 39% to 15%. In exchange, Swiss firms committed to at least $200 billion in US investments over five years, with a minimum of $67 billion earmarked for 2026 alone. The $27 billion already deployed means they are roughly 40% of the way to that annual target, and it is only April.
Pharma giants are writing the biggest checks
Roche announced a staggering $50 billion commitment for US-based manufacturing and research and development. Novartis is not far behind, pledging $23 billion across ten separate facilities in the United States. The Swiss-American Chamber of Commerce is actively tracking the investment flows, and the numbers have been reported by outlets including NZZ am Sonntag, Switzerland’s prominent Sunday newspaper.
Inside the tariff deal
The November 2025 agreement came amid escalating trade tensions initiated by the Trump administration, which had pushed Swiss tariffs to a punishing 39%. The resulting framework cut that rate to 15%. The deal also includes Liechtenstein, the tiny principality sandwiched between Switzerland and Austria, which shares a customs union with its larger neighbor. Beyond the tariff reduction itself, the agreement is designed to enhance access for US exporters to Swiss markets. Further negotiations are ongoing to finalize a long-term trade accord.
